Title:
ONCOLYTIC VIRUS REGIMENS FOR THE TREATMENT OF CANCER
Document Type and Number:
WIPO Patent Application WO/2023/141229
Kind Code:
A3
Abstract:
The addition of lerapolturev in a very specific dosage regimen in combination with a checkpoint inhibitor provides superior results in the treatment of a cancer or a tumor. The unexpected discovery is that the specifically-timed administration of selectively high-dosed lerapolturev in combination with an immune checkpoint inhibitor has a profound effect on the immune cells in the cancer microenvironment.
More Like This:
| JPWO2006013923 | Therapeutic agent for arthritis with autoimmune disease |
| JP4828940 | Cell transport compositions and their use |
| WO/2024/114687 | ANTI-TFR1 ANTIBODIES AND USES THEREOF |
Inventors:
CORUM DANIEL (US)
MORRIS SHANNON (US)
MORRIS SHANNON (US)
Application Number:
PCT/US2023/011176
Publication Date:
August 24, 2023
Filing Date:
January 19, 2023
Export Citation:
Assignee:
ISTARI ONCOLOGY INC (US)
International Classes:
A61K39/395; A61K35/768; A61P35/00; C07K16/28; C07K16/30
Foreign References:
| US20210106633A1 | 2021-04-15 | |||
| US20190070233A1 | 2019-03-07 |
Attorney, Agent or Firm:
BELLOWS, Brent, R. et al. (US)
Download PDF: